enGenes presenting X-cite Continuous Manufacturing technology to EFIB 2021 Vienna

Recombinant protein specialist manufacturer enGenes Biotech GmbH (enGenes) will present its innovative decoupled Continuous Manufacturing (CM) protein expression technology to the upcoming European Forum for Industrial Biotechnology & the Bioeconomy (EFIB 2021) meeting in Vienna.

This is a return to EFIB for enGenes, who made their first Forum appearance in 2019.

enGenes X-cite Continuous Manufacturing breakthrough

enGenes will also participate across the range of face-to-face and virtual partnering meetings hosted at the EFIB Forum.

Dr. Mairhofer, enGenes CEO and co-founder, will also be one of the panel of speakers during Day Two’s Parallel Session B on ‘Bioprocesses: Next-generation impact on industrial manufacturing’ (October 7: 1100-1215 hrs. CET).

He will explain how enGenes-X-cite CM technology, on which the company has recently filed a patent application, is based on its equally innovative X-press expression platform.

Bringing cell line stability to CM

“Conventional E. coli cell lines are not stable under continuous production conditions and product yields decline quickly. But by decoupling protein production from cell growth we can genetically stabilize the manufacturing process and develop microbial continuous production processes that are superior over continuous processes using conventional host cells,” Dr. Mairhofer explained.

“enGenes-X-cite allows substantially higher yields and extended productivity. This allows us to develop production processes that are highly cost-effective and allow for process intensification since they can be run in smaller equipment compared to conventional fed-batch processes,” he noted.

About enGenes Biotech

enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes, including its proprietary enGenes-X-press™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-X-press™ has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.

enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.

About EFIB 2021

The annual European Forum for Industrial Biotechnology & the Bioeconomy (EFIB) has become one of Europe’s leading event for the bio-based economy.

The partnering forum brings together more than 500 delegates from some 30 countries and 280 business, policy and science organisations to discuss emerging trends in industrial biotechnology.

EFIB 2021 is a two-day event opening October 6 at the state-of-the-art Austria Centre Vienna, one of Europe’s first green conference centers.

The 2021 Forum will be themed on ‘Delivering the EU Green Deal: Industrial biotechnology into business’, taking stock of progress 18 months on from the EC’s publication of the EU  Green Deal document. It will feature more than 70 speakers spread across more than ten  focused plenary and parallel tracks as well as roundtable sessions.

Organizer is Europa Bio with further information at:  https://efibforum.com


Click on Decoupling of recombinant protein production from Escherichia coli cell growth  for relevant research study.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.